Restless Legs Syndrome

Restless Legs Syndrome (RLS) is a real, well-recognized neurological condition — not nervousness, not "all in your head," and not simply a habit of fidgeting. People with RLS feel a powerful, often hard-to-describe urge to move their legs, usually along with uncomfortable sensations, and it characteristically strikes when they are resting in the evening or trying to fall asleep. It is common, frequently runs in families, and is closely tied to how the brain uses iron and dopamine. The good news: it is diagnosable from your story alone, and most people improve once iron is checked and corrected and the right treatment approach is chosen. This page explains what RLS is, how it is diagnosed, why iron matters so much, and how treatment guidance has recently shifted — including an honest look at a long-term medication risk called augmentation.

Table of Contents

  1. What Restless Legs Syndrome Is
  2. Symptoms & How It's Diagnosed
  3. Causes & Triggers
  4. The Iron Connection
  5. Treatment
  6. Lifestyle & Self-Care
  7. When to See a Doctor
  8. Research Papers
  9. Connections
  10. Featured Videos

What Restless Legs Syndrome Is

Restless Legs Syndrome is a neurological sensorimotor disorder: a problem in the way the nervous system controls sensation and movement. Its central feature is an irresistible urge to move the legs, almost always paired with uncomfortable feelings deep inside the legs. People describe these sensations in many ways — crawling, creeping, tingling, pulling, aching, itching under the skin, or an electric, "fizzy" restlessness. The feelings are usually hard to put into words, which is one reason the condition was misunderstood for so long.

RLS is also known as Willis-Ekbom disease, named for the two physicians who described it (Sir Thomas Willis in the 1600s and Karl-Axel Ekbom in the 1940s). The renaming was meant to signal something important: this is a genuine medical condition with a biological basis, not a behavioral quirk or a sign of anxiety. If you have RLS, your symptoms are real and explainable.

It is also common. Across large population studies, roughly 5–10% of adults have RLS, and a recent global analysis estimated the pooled prevalence at about 7% of adults — hundreds of millions of people worldwide. It becomes more frequent with age and is consistently about twice as common in women as in men, partly because pregnancy is a well-known trigger. Symptoms range from a mild, occasional annoyance to a nightly ordeal that seriously disrupts sleep and daily life.

Symptoms & How It's Diagnosed

RLS is a clinical diagnosis: there is no blood test, scan, or sleep study that confirms it. Instead, doctors use five well-established criteria from the International Restless Legs Syndrome Study Group (IRLSSG). All five must be present:

  1. Urge to move the legs, usually accompanied by uncomfortable or unpleasant sensations in the legs.
  2. The urge and sensations begin or get worse during rest or inactivity — when lying down or sitting still.
  3. The urge and sensations are partially or completely relieved by movement, such as walking, stretching, or pacing — at least for as long as the movement continues.
  4. The urge and sensations are worse in the evening or at night than during the day, or happen only in the evening or night.
  5. These features are not better explained by another condition — for example leg cramps, positional discomfort, arthritis, swelling, or the leg discomfort of poor circulation.

That fifth point matters. Several other problems can mimic RLS, so part of the diagnosis is making sure something else isn't the real cause. A good clinician will ask careful questions, review your medications, and usually check your iron levels (more on that below).

Two related issues often travel with RLS. The first is periodic limb movements of sleep (PLMS) — repetitive jerking or twitching of the legs during sleep that the person is often unaware of, but a bed partner may notice. The second is the broader toll on sleep: because symptoms peak at bedtime, RLS frequently causes trouble falling asleep, fragmented sleep, and daytime fatigue. For many people, the lost sleep is the most disabling part.

Causes & Triggers

RLS comes in two broad forms. Primary (idiopathic) RLS often runs in families and tends to begin earlier in life; if a parent or sibling has it, your risk is higher, and researchers have identified specific genes linked to the condition. Secondary RLS is driven or worsened by another medical situation — and this form is especially important because the underlying cause can often be treated.

The major contributors to secondary RLS include:

A number of everyday substances and medications can aggravate RLS or unmask it:

If your RLS started or worsened around the time you began a new medication, that connection is worth raising with your doctor — but do not stop a prescribed medication on your own.

The Iron Connection

Iron is central to understanding RLS. The brain needs iron to manufacture dopamine, a chemical messenger involved in controlling movement. In RLS, the problem is not usually a lack of iron in the blood but a shortage of iron available to the brain — which is why you can have low brain iron even with a "normal" blood count and no anemia.

Because of this, guidelines recommend that everyone with clinically significant RLS have their iron status checked — specifically serum ferritin (a measure of iron stores) and transferrin saturation (a measure of iron available for use). Ferritin can be falsely raised by inflammation, so it is interpreted alongside the other results.

When iron stores are low, iron supplementation can meaningfully improve RLS. Expert guidelines commonly suggest treating with iron when ferritin is below about 75 ng/mL (or transferrin saturation is under 20%) — a higher threshold than is used for ordinary anemia, because the brain in RLS seems to need fuller iron stores. Depending on the levels and the situation, this may be oral iron or, in some cases, intravenous (IV) iron given under medical supervision.

An honest caveat: iron repletion helps a meaningful subset of people with RLS, not everyone. It is most likely to help when stores are genuinely low, and the benefit can take weeks to months to appear. It is one of the most important first steps — but it is not a guaranteed cure, and iron should never be taken blindly (see When to See a Doctor).

Treatment

Treatment is built up in steps. The starting points for almost everyone are correcting low iron (if your ferritin or transferrin saturation is low) and removing aggravating factors — reviewing medications that can worsen RLS and cutting back on caffeine, alcohol, and nicotine. For milder or intermittent symptoms, these measures plus the lifestyle steps below may be enough.

When medication is needed, the recommended approach has shifted in recent years. The current first-line drug class is the alpha-2-delta ligands (also called gabapentinoids): gabapentin enacarbil, pregabalin, and gabapentin. The 2025 American Academy of Sleep Medicine (AASM) clinical practice guideline gives these a strong recommendation and positions them as preferred initial therapy for many adults. They tend to help both the leg sensations and the associated sleep disruption, and they do not carry the particular long-term risk described next.

The other established class is the dopamine agonists — pramipexole, ropinirole, and rotigotine (a skin patch). These drugs genuinely work in the short term and were once the automatic first choice. But over months to years of use, a significant minority of patients develop augmentation, and this has changed expert thinking.

What is augmentation? It is a paradoxical, drug-induced worsening of RLS. Over time the medication makes the disease behave worse than it did before treatment. Specifically, symptoms tend to:

The cruel trap of augmentation is that the worsening can look like the disease progressing, tempting both patient and prescriber to raise the dose — which often makes augmentation worse. Because of this risk, modern guidelines, including the AASM 2025 guideline, recommend against using dopamine agonists as routine first-line therapy and advise discussing augmentation with anyone already on them, with a plan to gradually taper off and switch to an alternative if needed. This is a real change from older guidance, which had placed dopamine agonists front and center.

Finally, for severe, refractory RLS that has not responded to iron, lifestyle measures, and the medications above, low-dose opioids can be effective. Because of their risks, they are reserved for difficult cases and used under specialist care with careful monitoring — not as an everyday treatment.

Lifestyle & Self-Care

Self-care will not cure moderate-to-severe RLS on its own, but it genuinely helps, and for milder cases it can be enough. Reasonable steps include:

When to See a Doctor

Consider seeing a clinician if any of the following apply:

Research Papers

  1. Winkelman JW, Berkowski JA, DelRosso LM, et al. (2025). Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 21(1):137–152. — The current guideline: strongly recommends alpha-2-delta ligands (gabapentin enacarbil, gabapentin, pregabalin) as first-line and recommends against routine dopamine-agonist use because of augmentation.
  2. Allen RP, Picchietti DL, Garcia-Borreguero D, et al. (2014). Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria. Sleep Medicine, 15(8):860–873. — The source of the five essential diagnostic criteria used worldwide to diagnose RLS.
  3. Allen RP, Picchietti DL, Auerbach M, et al. (2018). Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Medicine, 41:27–44. — Sets out how and when to test iron and treat it, including the commonly cited ferritin threshold (≤75 ng/mL) and transferrin saturation (<20%).
  4. Winkelman JW, Armstrong MJ, Allen RP, et al. (2016). Practice guideline summary: treatment of restless legs syndrome in adults — report of the American Academy of Neurology. Neurology, 87(24):2585–2593. — The prior major U.S. guideline (now superseded by the 2025 AASM guideline above); useful historical context for how recommendations have evolved.
  5. Song P, Cui X, Bai L, et al. (2024). The global and regional prevalence of restless legs syndrome among adults: a systematic review and modelling analysis. Journal of Global Health, 14:04113. — Estimates a pooled global prevalence of about 7% of adults, higher in women (≈8.3%) than men (≈6.0%).
  6. Silber MH, Buchfuhrer MJ, Earley CJ, et al. (2021). The management of restless legs syndrome: an updated algorithm. Mayo Clinic Proceedings, 96(7). — A practical, widely used treatment algorithm emphasizing iron, trigger reduction, alpha-2-delta ligands, and the avoidance/recognition of augmentation.

Back to Table of Contents

Connections

Back to Table of Contents